


RealRate

PHARMACEUTICAL 2021

Dyne Therapeutics Inc. Rank 17 of 402







RealRate

## Dyne Therapeutics Inc. Rank 17 of 402

The relative strengths and weaknesses of Dyne Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dyne Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 64% points. The greatest weakness of Dyne Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 291%, being 243% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	349,087
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,967
Liabilities, Non-Current	0
Other Assets	2,301
Other Compr. Net Income	-27
Other Expenses	0
Other Liabilities	0
Other Net Income	-790
Other Revenues	0
Property and Equipment	1,946
Research and Development	45,200
Selling, General and Administrative Expense	13,447

Output Variable	Value in 1000 USD
Assets	353,334
Liabilities	10,967
Expenses	58,647
Revenues	0
Stockholders Equity	342,367
Net Income	-59,437
Comprehensive Net Income	-59,450
Economic Capital Ratio	291%

